Keywords
hormones
metabolic
hospitalization
Colombia
How to Cite
Abstract
Introduction: Data on the impact of human immunodeficiency virus (HIV) infection on a hormonal, metabolic and haematological level in patients hospitalized in Colombia are scarce. Objective: To describe the hormonal, metabolic and haematological profile of HIV patients hospitalized in a third level institution. Material and method: Cross-sectional observational study, which included sociodemographic, clinical, hormonal, metabolic and hematological variables of patients with HIV between 2013 and 2014. Results: We included 52 patients, 34 men, with an average age of 40 years (SD 12.6, Min: 21 Max: 79). 23% had tuberculosis, 13% had cerebral toxoplasmosis. 26 patients had a history of toxic consumption: cigarette (58%), alcohol (27%) and hallucinogenic substances (15%). 14% of the patients received antiretroviral therapy at admission, mainly with protease inhibitors. Other medications used were: trimethoprim-sulfamethoxazole (27.2%) and antituberculous drugs (15%). The main causes of hospitalization were cerebral toxoplasmosis (31%) and tuberculosis (15%). 52% of the population had Wasting syndrome. The time of diagnosis of HIV was <1 year in 48% of the population. 79% of the patients had a CD4 count <200 cell/mm3 (SD 199, Min: 3 Max: 641). In the hormonal profile, 58% (29 patients) presented alteration of the thyroid axis, of which 14 session profile of central hypothyroidism. 55.8% of men had hyperprolactinemia. The metabolic profile was characterized by hypertriglyceridemia (44%) and low HDL (81%). The most frequent electrolyte alteration was hyponatremia (37%). Conclusions: In the population of patients hospitalized with HIV, endocrine alterations were found suggesting primary glandular, pituitary and adrenal involvement, with lipid and electrolyte alterations largely related to advanced disease.
References
2. Sistema Nacional de Vigilancia en Salud Pública (SIVIGILA). Boletín epidemiológico semanal número 52 de 2016.
3. Agudelo-Gonzalez S, Murcia-Sanchez F, Salinas D, Osorio J. Infecciones oportunistas en pacientes con VIH en el hospital universitario de Neiva, Colombia. 2007-2012. Infectio. 2015; 19(2): 52-59. doi: http://dx.doi.org/10.1016/j.infect.2014.11.008.
4. Madge S, Smith CJ, Lampe FC, Thomas M, Johnson MA, Youle M, et al. No association between HIV disease and its treatment and thyroid function. HIV Med. 2007; 8(1): 22-27. doi: 10.1111/j.1468-1293.2007.00422.x.
5. Kasonde M, Niska RW, Rose C, Henderson FL, Segolodi TM, Turner K, et al. Bone mineral density changes among HIV-uninfected young adults in a randomised trial of Pre-Exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana. PLoS ONE. 2014; 9(3): e90111. doi: 10.1371/journal.pone.0090111.
6. Granados C, Álvarez C, Prada G, Martínez F, Sarmiento C. Guía para el manejo de VIH/SIDA basada en la evidencia Colombia. 215; 1: 242.
7. Lamptey P, Johnson J, Khan M. El desafío mundial del VIH y el SIDA Washington, DC: Population Reference Bureau. 2006; 61(1): 28.
8. Bongiovanni M, Adorni F, Casana M, Tordato F, Tincati C, Cicconi P, et al. Subclinical hypothyroidism in HIV-infected subjects. J Antimicrob Chemother. 2006; 58(5): 1086-1089. doi: 10.1093/jac/dkl360.
9. Drnovsek ML, Portunato GB, San Martín PR, Virga MR, Losso M, Toibaro J, et al. Alteraciones endocrinometabólicas en pacientes ambulatorios con infección por Virus de la Inmunodeficiencia Humana. Rev Argent Endocrinol Metab. 2016; 53(4), 121-127. doi: 10.1016/j.raem.2016.09.002.
10. Chrousos GP, Zapanti ED. Hypothalamic-Pituitary-Adrenal Axis in HIV Infection and Disease. Endocrinol Metab Clin North Am. 2014; 43(3): 791-806. doi: 10.1016/j.ecl.2014.06.002.
11. Rochira V, Guaraldi G. Hypogonadism in the HIV-infected man. Endocrinolo Metabol Clin North Am. 2014; 43(3): 709-730. doi: 10.1016/j.ecl.2014.06.005.
12. Abelleira E, De Cross GA, Pitoia F. Disfunción tiroidea en adultos infectados por el Virus de Inmunodeficiencia Humana. Med B Aires. 2014; 74(4): 315-320.
13. Guerra M, Alvarado M, Fonseca VL, Valbuena V. Comportamiento del metabolismo lipídico en pacientes con VIH/SIDA de Bogotá. Universitas Scientiarum, Rev Fac Ciencias. 2007; 12(2): 47-56.
14. Mittal A, Achappa B, Madi D, Chowta MN, Ramapuram JT, Rao S, et al. The development of metabolic risk factors after the initiation of the second line anti-retroviral therapy. J Clin
Diagn Res. 2013; 7(2): 265-268. doi: 10.7860/JCDR/2013/4740.2743.
15. Rossibell Berenisse OA. Tesis de grado: Alteraciones lipídicas en pacientes VIH/SIDA en terapia antiretroviral (lpv/rpv). Unidad técnica de infectología, Hospital Teodoro Maldonado Carbo. Guayaquiel Ecuador. 2014.
16. Gómez CH, Vesga JF, Lowenstein E, Suárez JO, Gil FA, Valderrama SL, et al. Detección de hipotiroidismo en un programa de atención de VIH/SIDA en un hospital de Bogotá, Colombia. Rev Chil Infectol. 2011; 28: 59-63. doi: http://dx.doi.org/10.4067/S0716-10182011000100011.
17. Jain G, Devpura G, Gupta BS. Abnormalities in the thyroid function tests as surrogate marker of advancing HIV infection in infected adults. J Assoc Physicians India. 2009; 57: 508-510.
18. Patterson S, Moran P, Epel E, Sinclair E, Kemeny ME, Deeks SG, et al. Cortisol patterns are associated with T cell activation in HIV. PLoS ONE. 2013; 8(7): e63429. doi: 10.1371/journal.pone.0063429.
19. Monroe AK, Dobs AS, Palella FJ, Kingsley LA, Witt MD, Brown TT. Morning free and total testosterone in HIV-infected men: implications for the assessment of hypogonadism. AIDS Res Ther. 2014; 22; 11(1): 6. doi: 10.1186/1742-6405-11-6.
20. Yalamanchi S, Dobs A, Greenblatt RM. Gonadal function and reproductive health in women with Human Immunodeficiency Virus infection. Endocrinol Metab Clin North Am. 2014; 43(3): 731-741. doi: 10.1016/j.ecl.2014.05.002.
21. Montero A, Bottasso OA, Luraghi MR, Giovannoni AG, Sen L. Association between high serum prolactin levels and concomitant infections in HIV-infected patients. Hum Immunol. 2001; 62(2): 191-196.
22. Montero A, Bottasso OA, Luraghi MR, Giovannoni AG, Sen L. Galactorrhoea, hyperprolactinaemia, and protease inhibitors. Lancet. 2001; 357(9254): 473-474. doi: 10.1016/S0140-6736(05)71275-7.
23. Dao CN, Peters PJ, Kiarie JN, Zulu I, Muiruri P, Ong’ech J, et al. Hyponatremia, hypochloremia, and hypoalbuminemia predict an increased risk of mortality during the first year of antiretroviral therapy among HIV-infected Zambian and Kenyan women. AIDS Res Hum Retroviruses. 2011; 27(11): 1149-1155. doi: 10.1089/AID.2010.0345.
24. Denue BA, Gashau W, Bello HS, Kida IM, Bakki B, Ajayi B. Relation between some haematological abnormalities, degree of immunosuppression and viral load in treatment-naive HIV-infected patients. East Mediterr Health J. 2013; 19(4): 362-368.
25. Firnhaber C, Smeaton L, Saukila N, Flanigan T, Gangakhedkar R, Kumwenda J, et al. Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas. Int J Infect Dis. 2010; 14(12): e1088-1092. doi: 10.1016/j.ijid.2010.08.002.
26. Wondimeneh Y, Muluye D, Ferede G. Prevalence and associated factors of thrombocytopenia among HAART naive HIV positive patients at Gondar university hospital, northwest Ethiopia. BMC Research Notes. 2014; 7: 5. doi: 10.1186/1756-0500-7-5.
27. Franzetti M, Adorni F, Oreni L, Van Den Bogaart L, Resnati C, Milazzo L, et al. Changes in the incidence of severe thrombocytopenia and its since the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2014; 67(5): 493-498. doi: 10.1097/QAI.0000000000000347.
28. Laguado Vera LD, Arenas M, Rodríguez M, Gómez JC, Bonilla RA, Rojas G. Parámetros hematológicos y recuento de células T-CD4+ en pacientes VIH con síntomas digestivos en Bucaramanga, Colombia. Rev Cub Hematol Inmunol Hemoter. 2016; 32(4).
29. Álvarez M, Villa JP, Hidron A, Ocampo A, Restrepo L, Eusse A, et al. Perfil epidemiológico y clínico de pacientes colombianos hospitalizados con VIH, enfermedades infecciosas del foro abierto. 2016; 3(suppl 1): 1531. doi: https://doi.org/10.1093/ofid/ofw172.1233.
Se autoriza la reproducción total o parcial de la obra para fines educativos, siempre y cuando se cite la fuente.
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Pública Internacional.